psoriasis. Objectives: In this study, serumlevels of IL-17 in psoriaticpatients was compared with healthy controls; besides, in patients with psoriasis, serumlevels of IL-17 were compared with pre-treatment levels, after topical treatments. Patients and Methods: In this case-control study, serumlevels of IL-17 were measured and compared in 30 psoriaticpatients and 30 healthy individuals matched to age, gender and body mass index. After evaluating the severity of …
Conclusion: In psoriatic patients, serum levels of IL-17 increased significantly compared to healthy subjects. Treatment of psoriasis with topical corticosteroids for four weeks reduced the serum level of IL-17 and the severity of disease.